| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/07/2023 | -14.45% | Morgan Stanley | $19.5 → $9 | Downgrades | Equal-Weight → Underweight |
| 11/03/2023 | 71.1% | JonesTrading | $22 → $18 | Maintains | Buy |
| 08/21/2023 | 99.62% | Stephens & Co. | → $21 | Reiterates | Equal-Weight → Equal-Weight |
| 08/04/2023 | 109.13% | JonesTrading | → $22 | Reiterates | Buy → Buy |
| 07/18/2023 | — | BTIG | Initiates Coverage On | → Neutral | |
| 07/05/2023 | 85.36% | Morgan Stanley | $24 → $19.5 | Maintains | Equal-Weight |
| 05/17/2023 | 109.13% | JonesTrading | → $22 | Reiterates | Buy → Buy |
| 05/09/2023 | 80.61% | Keefe, Bruyette & Woods | $20 → $19 | Maintains | Market Perform |
| 05/08/2023 | 99.62% | Stephens & Co. | → $21 | Reiterates | → Equal-Weight |
| 02/21/2023 | 99.62% | Stephens & Co. | $28 → $21 | Downgrades | Overweight → Equal-Weight |
| 11/07/2022 | 147.15% | Stephens & Co. | $27 → $26 | Maintains | Overweight |
| 09/26/2022 | 166.16% | JonesTrading | $34 → $28 | Maintains | Buy |
| 05/12/2022 | 128.14% | Morgan Stanley | $26.5 → $24 | Maintains | Equal-Weight |
| 05/02/2022 | 223.19% | JonesTrading | $38 → $34 | Maintains | Buy |
| 03/09/2022 | 170.91% | Morgan Stanley | $30.5 → $28.5 | Maintains | Equal-Weight |
| 03/02/2022 | 261.22% | JonesTrading | → $38 | Initiates Coverage On | → Buy |
| 12/09/2021 | 189.92% | Morgan Stanley | $33.5 → $30.5 | Maintains | Equal-Weight |
| 09/22/2021 | 218.44% | Morgan Stanley | $40 → $33.5 | Downgrades | Overweight → Equal-Weight |
| 07/21/2021 | 289.73% | Berenberg | → $41 | Initiates Coverage On | → Buy |
| 01/05/2021 | 280.23% | Morgan Stanley | $37 → $40 | Maintains | Overweight |
| 12/21/2020 | 242.21% | JP Morgan | $27 → $36 | Upgrades | Underweight → Neutral |
| 08/10/2020 | 280.23% | Stephens & Co. | $39 → $40 | Maintains | Overweight |
| 05/08/2020 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 03/13/2020 | 261.22% | Stephens & Co. | → $38 | Upgrades | Equal-Weight → Overweight |
| 02/26/2020 | 251.71% | Morgan Stanley | $39 → $37 | Maintains | Overweight |
| 09/16/2019 | 280.23% | JMP Securities | → $40 | Upgrades | Market Perform → Market Outperform |
| 08/21/2019 | — | Craig-Hallum | Upgrades | Hold → Buy | |
| 08/06/2019 | — | Compass Point | Downgrades | Buy → Neutral | |
| 08/05/2019 | 251.71% | Stephens & Co. | $31 → $37 | Maintains | Equal-Weight |
| 01/24/2019 | — | Compass Point | Initiates Coverage On | → Neutral | |
| 11/19/2018 | 242.21% | Morgan Stanley | → $36 | Upgrades | Equal-Weight → Overweight |
What is the target price for RE/MAX Hldgs (RMAX)?
The latest price target for RE/MAX Hldgs (NYSE: RMAX) was reported by Morgan Stanley on November 7, 2023. The analyst firm set a price target for $9.00 expecting RMAX to fall to within 12 months (a possible -14.45% downside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for RE/MAX Hldgs (RMAX)?
The latest analyst rating for RE/MAX Hldgs (NYSE: RMAX) was provided by Morgan Stanley, and RE/MAX Hldgs downgraded their underweight rating.
When is the next analyst rating going to be posted or updated for RE/MAX Hldgs (RMAX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of RE/MAX Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for RE/MAX Hldgs was filed on November 7, 2023 so you should expect the next rating to be made available sometime around November 7, 2024.
Is the Analyst Rating RE/MAX Hldgs (RMAX) correct?
While ratings are subjective and will change, the latest RE/MAX Hldgs (RMAX) rating was a downgraded with a price target of $19.50 to $9.00. The current price RE/MAX Hldgs (RMAX) is trading at is $10.52, which is out of the analyst's predicted range.